Once a deadly global epidemic, Hepatitis C can now be treated with innovative new treatments.
Baird’s CMC is working with stakeholders across industry and policy to promote access to these important new therapies and support public health efforts to eradicate the virus.
Known as the “silent killer,” Hepatitis C’s first infection can be so mild it passes without notice. Some are lucky and escape chronic infection, but in some people, it remains invisible, persisting for years until deadly and debilitating liver failure, cancer or cirrhosis emerge.
New treatments are very effective at clearing the virus, but they seem expensive. Only just introduced, their value to health systems and society could be immense: they have the potential to avoid some of the most costly cases in modern healthcare systems.
Producers of these treatments are developing new approaches to reimbursement in low and middle income countries, which may well become a model for other treatments in other diseases in the future.
Baird’s CMC has worked with pharmaceutical companies, not-for-profits, foundations, grant giving bodies and patient advocacy groups to make these innovative new treatments accessible.
We have worked with policy makers and patient advocacy groups across the world to promote public health initiatives to tackle Hep C at all levels.
We have worked with a top ten pharmaceutical company to identify civil society partners n 24 low and middle income countries and, in several of them, to help our client start to build innovative new models of corporate citizenship alongside these partners.
Some 150 million people worldwide are chronically infected with hepatitis C virus, and more than 350,000 people are estimated to die from hepatitis C-related liver diseases each year.
World Health Organization
At Baird’s CMC our knowledge of Hep C is unparalleled, covering all sectors and addressing all kinds of issues, from clinical decision making, to treatment access and reimbursement, to raising public awareness.
If you are grappling with the complexity of delivering a response to Hep C, we can help you map a clear path for action, deliver effective communications and build lasting, productive relationships.
Contact your Regional Baird’s CMC lead and find out how to leverage our best thinking in your work on Hepatitis C.